This site is intended for health professionals only

Phase III trials of Fycompa®


An official press briefing to share updates on Eisai’s epilepsy portfolio at the ExCel Centre, London briefing will be held on 1 October 2012 between 12.30pm and 2.25pm.
The press briefing will focus on the new pooled data from Phase III trials of Fycompa®▼(perampanel) – the newest anti-epileptic drug (AED) first in new class epilepsy treatments, an update on data supporting Zonegran® (zonisamide)* as a monotherapy and topline results from investigations in children, as well as giving insights into to the clinical development programme for Zebinix®* (eslicarbazepine acetate).**
Professor Mike Kerr, Clinical Professor at the Institute of Psychological Medicine and Clinical Neurosciences in Cardiff, Wales will chair the sessions, in addition to  many other experts available for media interviews.
*   Zonegran is under license from Dainippon Sumitomo Pharma.
** Zebinix (eslicarpazepine acetate) is currently under licence from BIAL.

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine